<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b085f4e8-f461-454e-9aff-4f18d9888a8b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information
needed to use AGGRENOX safely and effectively. See full prescribing
information for AGGRENOX.<br/>
      <br/>AGGRENOX® (aspirin/extended-release
dipyridamole) Capsules<br/>Initial U.S. Approval: 1999<br/>
   </title>
   <effectiveTime value="20160806"/>
   <setId root="f07c8535-f9fb-4697-9b63-1ab22210efc9"/>
   <versionNumber value="3"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="079239644" root="1.3.6.1.4.1.519.1"/>
            <name>Carilion Materials Management</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="079239644" root="1.3.6.1.4.1.519.1"/>
                        <name>Carilion Materials Management</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="REPACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68151-3971" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5ce1d212-8c3f-47c9-85a7-2621dda1a0b9"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20160726"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68151-3971" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Aggrenox</name>
                        <formCode code="C42916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>aspirin and dipyridamole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0597-0001" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="R16CO5Y76E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ASPIRIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="R16CO5Y76E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ASPIRIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="64ALC7F90C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIPYRIDAMOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="64ALC7F90C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DIPYRIDAMOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value=" 1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68151-3971-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19991219"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020884" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19991219"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RED" xsi:type="CE">
                              <originalText>red</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>ivory</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>capsule</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="24" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">01A;</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="2f0a7b66-e112-4239-b529-b785bdedd11b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="p18122">AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.</paragraph>
               </text>
               <effectiveTime value="20120307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l22122" listType="unordered" styleCode="Disc">
                           <item>AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis <linkHtml href="#Section_1">(1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="6ea4370c-d171-496e-a2c5-3028ea31c5a5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="p36122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">AGGRENOX is not interchangeable with the individual components of aspirin and dipyridamole tablets. </content>
                     </content>
                  </paragraph>
                  <paragraph ID="p43122">The recommended dose of AGGRENOX is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. AGGRENOX can be administered with or without food.</paragraph>
               </text>
               <effectiveTime value="20120307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l47122" listType="unordered" styleCode="Disc">
                           <item>One capsule twice daily (morning and evening) with or without food <linkHtml href="#Section_2">(2)</linkHtml>
                           </item>
                           <item>In case of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning; resume BID dosing within one week <linkHtml href="#Section_2">(2)</linkHtml>
                           </item>
                           <item>Do not chew capsule <linkHtml href="#Section_2">(2)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">Not interchangeable with the individual components of aspirin and dipyridamole tablets </content>
                              </content>
                              <linkHtml href="#Section_2">(2)</linkHtml>
                           </item>
                           <item>Dispense in this unit-of-use container <linkHtml href="#Section_16">(16)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="bf5b0707-8cbe-4f0f-864e-f83b71a87895"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Alternative Regimen in Case of Intolerable Headaches</title>
                     <text>
                        <paragraph ID="p295122">In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and headaches become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="e74ca688-97f9-4ad3-b685-7f820b866e53"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="p303122">25 mg/200 mg capsules with a red cap and
an ivory-colored body, containing yellow extended-release pellets
incorporating dipyridamole and a round white tablet incorporating
immediate-release aspirin. The capsule body is imprinted in red with
the Boehringer Ingelheim logo and with "01A".</paragraph>
               </text>
               <effectiveTime value="20120307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l513122" listType="unordered" styleCode="Disc">
                           <item>Capsule: 25 mg aspirin/200 mg extended-release dipyridamole <linkHtml href="#Section_3">(3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="751f0320-0adf-4fcc-90af-b5deca89f75d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <effectiveTime value="20151117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l528122" listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity to any product ingredients <linkHtml href="#Section_4.1">(4.1)</linkHtml>
                           </item>
                           <item>Patients with known allergy to NSAIDs <linkHtml href="#Section_4.2">(4.2)</linkHtml>
                           </item>
                           <item>Patients with the syndrome of asthma, rhinitis, and nasal
polyps <linkHtml href="#Section_4.2">(4.2)</linkHtml>
                           </item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_4.1">
                     <id root="54efae24-7980-4c0e-98e2-b5b314a5757f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1  Hypersensitivity</title>
                     <text>
                        <paragraph ID="p554122">AGGRENOX is contraindicated in patients with known hypersensitivity to any of the product components.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_4.2">
                     <id root="e03b515a-1ca7-470b-93a0-3cdd076d44b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2  Allergy</title>
                     <text>
                        <paragraph ID="p768122">Aspirin is contraindicated in patients with
known allergy to nonsteroidal anti-inflammatory drug (NSAID) products
and in patients with the syndrome of asthma, rhinitis, and nasal polyps.
Aspirin may cause severe urticaria, angioedema or bronchospasm.</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_4.3">
                     <id root="9d044c63-3405-45c0-97b2-6c27878b1435"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3  Reye Syndrome</title>
                     <text>
                        <paragraph ID="p776122">Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="0fdc1c2a-bcda-400e-addb-1730afa4082a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20151117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l785122" listType="unordered" styleCode="Disc">
                           <item>AGGRENOX increases the risk of bleeding <linkHtml href="#Section_5.1">(5.1)</linkHtml>
                           </item>
                           <item>Avoid use in patients with severe hepatic or renal insufficiency <linkHtml href="#Section_5.2">(5.2</linkHtml>, <linkHtml href="#Section_5.3">5.3)</linkHtml>
                           </item>
                           <item>Can cause fetal harm when administered to a pregnant woman, especially in the third trimester <linkHtml href="#Section_5.4">(5.4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="c92afd8a-5dd1-4a1a-9814-ff6993465905"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Risk of Bleeding</title>
                     <text>
                        <paragraph ID="p22046422">AGGRENOX increases the risk of bleeding.
Risk factors for bleeding include the use of other drugs that increase
the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin,
anagrelide, fibrinolytic therapy, and chronic use of NSAIDs) [<content styleCode="italics">see Drug Interactions <linkHtml href="#Section_7.1">(7.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph ID="p1027122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Intracranial
Hemorrhage</content>
                           </content>
                           <br/>In European Stroke Prevention
Study-2 (ESPS2), the incidence of intracranial hemorrhage was 0.6%
in the AGGRENOX group, 0.5% in the extended-release dipyridamole (ER-DP)
group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups.</paragraph>
                        <paragraph ID="p1054122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Gastrointestinal (GI)
Side Effects</content>
                           </content>
                           <br/>GI side effects include
stomach pain, heartburn, nausea, vomiting, and gross GI bleeding.
Although minor upper GI symptoms, such as dyspepsia, are common and
can occur anytime during therapy, physicians should remain alert for
signs of ulceration and bleeding, even in the absence of previous
GI symptoms. Inform patients about the signs and symptoms of GI side
effects and what steps to take if they occur.</paragraph>
                        <paragraph ID="p1063122">In ESPS2, the incidence of gastrointestinal bleeding
was 4.1% in the AGGRENOX group, 2.2% in the extended-release dipyridamole
group, 3.2% in the aspirin group, and 2.1% in the placebo groups. </paragraph>
                        <paragraph ID="p1066122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Peptic Ulcer Disease</content>
                           </content>
                           <br/>Avoid using aspirin in patients with a history
of active peptic ulcer disease, which can cause gastric mucosal irritation
and bleeding.</paragraph>
                        <paragraph ID="p1281122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Alcohol Warning</content>
                           </content>
                           <br/>Because AGGRENOX contains
aspirin, counsel patients who consume three or more alcoholic drinks
every day about the bleeding risks involved with chronic, heavy alcohol
use while taking aspirin.</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="f7c6f735-7fd3-4c91-a230-4a1393d710a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Renal Failure</title>
                     <text>
                        <paragraph ID="p1295122">Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [<content styleCode="italics">
                              <content styleCode="emphasis">see Use in Specific Populations <linkHtml href="#Section_8.6">(8.6)</linkHtml> and Clinical Pharmacology <linkHtml href="#Section_12.3">(12.3)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="f1f17959-917e-4fcc-a2dc-249b606fd435"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Hepatic Insufficiency</title>
                     <text>
                        <paragraph ID="p1316122">Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [<content styleCode="italics">
                              <content styleCode="emphasis">see Use in Specific Populations <linkHtml href="#Section_8.6">(8.6)</linkHtml> and Clinical Pharmacology <linkHtml href="#Section_12.3">(12.3)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="730f4031-d8fe-4523-be7b-6b24fea5cc58"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>5.4  Pregnancy</title>
                     <text>
                        <paragraph ID="p1543122">Because AGGRENOX contains aspirin, AGGRENOX can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid AGGRENOX in the third trimester of pregnancy [<content styleCode="italics">
                              <content styleCode="emphasis">see Use in Specific Populations <linkHtml href="#Section_8.1">(8.1)</linkHtml>
                              </content>
                           </content>].</paragraph>
                        <paragraph ID="p1555122">Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m<sup>2</sup> basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of AGGRENOX. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m<sup>2</sup> basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of AGGRENOX in pregnant women. If AGGRENOX is used during pregnancy, or if the patient becomes pregnant while taking AGGRENOX, inform the patient of the potential hazard to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="8f4f7923-79b0-4d82-a7aa-b9941a74ee92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5  Coronary Artery Disease</title>
                     <text>
                        <paragraph ID="p1571122">Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.</paragraph>
                        <paragraph ID="p1574122">For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="38160aae-cfd8-4d85-9218-d4f17027781c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6  Hypotension</title>
                     <text>
                        <paragraph ID="p1582122">Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="9e712d36-6d0d-4bcf-87b4-1db141c56c33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7  General</title>
                     <text>
                        <paragraph ID="p1796122">AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="ef1c295f-fb47-484f-9385-f28154ddab47"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="p1804122">The following adverse reactions are discussed
elsewhere in the labeling:</paragraph>
                  <list ID="l1807122" listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity [<content styleCode="italics">
                           <content styleCode="emphasis">see Contraindications <linkHtml href="#Section_4.1">(4.1)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Allergy [<content styleCode="italics">
                           <content styleCode="emphasis">see Contraindications <linkHtml href="#Section_4.2">(4.2)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Risk of Bleeding [<content styleCode="italics">
                           <content styleCode="emphasis">see Warnings and Precautions <linkHtml href="#Section_5.1">(5.1)</linkHtml>
                           </content>
                        </content>]</item>
                  </list>
               </text>
               <effectiveTime value="20151117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l2052122" listType="unordered" styleCode="Disc">
                           <item>The most frequently reported adverse reactions (&gt;10% and
greater than placebo) were headache, dyspepsia, abdominal pain, nausea,
and diarrhea <linkHtml href="#Section_6">(6)</linkHtml>
                           </item>
                        </list>
                        <paragraph ID="p2060122">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS,
contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257
or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="0cb2bf3a-09ff-4fb6-93bd-af84539e575d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1  Clinical Trials
Experience</title>
                     <text>
                        <paragraph ID="p2073122">Because clinical
trials are conducted under widely varying conditions, adverse reaction
rates observed in the clinical trials of a drug cannot be directly
compared to rates in the clinical trials of another drug and may not
reflect the rates observed in practice.</paragraph>
                        <paragraph ID="p2076122">The efficacy and safety of AGGRENOX was established
in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind,
placebo-controlled study that evaluated 6602 patients over the age
of 18 years who had a previous ischemic stroke or transient ischemic
attack within ninety days prior to entry. Patients were randomized
to either AGGRENOX, aspirin, ER-DP, or placebo [<content styleCode="italics">
                              <content styleCode="emphasis">see Clinical Studies <linkHtml href="#Section_14">(14)</linkHtml>
                              </content>
                           </content>]; primary endpoints included stroke (fatal or nonfatal)
and death from all causes.</paragraph>
                        <paragraph ID="p2088122">This
24-month, multicenter, double-blind, randomized study (ESPS2) was
conducted to compare the efficacy and safety of AGGRENOX with placebo,
extended-release dipyridamole alone and aspirin alone. The study was
conducted in a total of 6602 male and female patients who had experienced
a previous ischemic stroke or transient ischemia of the brain within
three months prior to randomization.</paragraph>
                        <paragraph ID="p2091122">Table 1 presents the incidence of adverse events that occurred in
1% or more of patients treated with AGGRENOX where the incidence was
also greater than in those patients treated with placebo. There is
no clear benefit of the dipyridamole/aspirin combination over aspirin
with respect to safety.</paragraph>
                        <table ID="t1" cellpadding="1" cellspacing="1" width="1229">
                           <caption>Table 1   Incidence of Adverse Events in ESPS2<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col align="left" width="43%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="7%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="6%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="6%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="6%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th> </th>
                                 <th align="left" colspan="8">Individual Treatment Group</th>
                              </tr>
                              <tr>
                                 <th align="left" styleCode="Toprule"> </th>
                                 <th colspan="2" styleCode="Toprule">AGGRENOX</th>
                                 <th colspan="2" styleCode="Toprule">ER-DP Alone</th>
                                 <th colspan="2" styleCode="Toprule">ASA Alone</th>
                                 <th colspan="2" styleCode="Toprule">Placebo</th>
                              </tr>
                              <tr>
                                 <th colspan="9" styleCode="Toprule">Body System/Preferred Term</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="9">
                                    <sup>a</sup>Reported
by ≥1% of patients during AGGRENOX treatment where the incidence was
greater than in those treated with placebo.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="8">Note:              ER-DP = extended-release
dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all
treatment groups is BID.<br/>                           NOS
= not otherwise specified.</td>
                                 <td> </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td> </td>
                                 <td colspan="2">1650</td>
                                 <td colspan="2">1654</td>
                                 <td colspan="2">1649</td>
                                 <td colspan="2">1649</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Botrule">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Total Number of
Patients</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Total Number (%) of Patients With
at<br/>Least One On-Treatment Adverse<br/>Event</content>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>1319</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>(80%)</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>1305</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>(79%)</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>1323</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>(80%)</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>1304</td>
                                 <td styleCode="Toprule">
                                    <br/>
                                    <br/>(79%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Central and Peripheral Nervous System
Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Headache</td>
                                 <td styleCode="Toprule">647</td>
                                 <td styleCode="Toprule">(39%)</td>
                                 <td styleCode="Toprule">634</td>
                                 <td styleCode="Toprule">(38%)</td>
                                 <td styleCode="Toprule">558</td>
                                 <td styleCode="Toprule">(34%)</td>
                                 <td styleCode="Toprule">543</td>
                                 <td styleCode="Toprule">(33%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Convulsions</td>
                                 <td styleCode="Toprule">28</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">15</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">28</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">26</td>
                                 <td styleCode="Toprule">(2%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Gastrointestinal System Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Dyspepsia</td>
                                 <td styleCode="Toprule">303</td>
                                 <td styleCode="Toprule">(18%)</td>
                                 <td styleCode="Toprule">288</td>
                                 <td styleCode="Toprule">(17%)</td>
                                 <td styleCode="Toprule">299</td>
                                 <td styleCode="Toprule">(18%)</td>
                                 <td styleCode="Toprule">275</td>
                                 <td styleCode="Toprule">(17%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Abdominal Pain</td>
                                 <td styleCode="Toprule">289</td>
                                 <td styleCode="Toprule">(18%)</td>
                                 <td styleCode="Toprule">255</td>
                                 <td styleCode="Toprule">(15%)</td>
                                 <td styleCode="Toprule">262</td>
                                 <td styleCode="Toprule">(16%)</td>
                                 <td styleCode="Toprule">239</td>
                                 <td styleCode="Toprule">(14%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Nausea</td>
                                 <td styleCode="Toprule">264</td>
                                 <td styleCode="Toprule">(16%)</td>
                                 <td styleCode="Toprule">254</td>
                                 <td styleCode="Toprule">(15%)</td>
                                 <td styleCode="Toprule">210</td>
                                 <td styleCode="Toprule">(13%)</td>
                                 <td styleCode="Toprule">232</td>
                                 <td styleCode="Toprule">(14%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Diarrhea</td>
                                 <td styleCode="Toprule">210</td>
                                 <td styleCode="Toprule">(13%)</td>
                                 <td styleCode="Toprule">257</td>
                                 <td styleCode="Toprule">(16%)</td>
                                 <td styleCode="Toprule">112</td>
                                 <td styleCode="Toprule">(7%)</td>
                                 <td styleCode="Toprule">161</td>
                                 <td styleCode="Toprule">(10%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Vomiting</td>
                                 <td styleCode="Toprule">138</td>
                                 <td styleCode="Toprule">(8%)</td>
                                 <td styleCode="Toprule">129</td>
                                 <td styleCode="Toprule">(8%)</td>
                                 <td styleCode="Toprule">101</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">118</td>
                                 <td styleCode="Toprule">(7%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Hemorrhage Rectum</td>
                                 <td styleCode="Toprule">26</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">22</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">13</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Melena</td>
                                 <td styleCode="Toprule">31</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">10</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">20</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">13</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule" valign="top">        Hemorrhoids</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">13</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">10</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">10</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        GI Hemorrhage</td>
                                 <td styleCode="Toprule">20</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">5</td>
                                 <td styleCode="Toprule">(0%)</td>
                                 <td styleCode="Toprule">15</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">7</td>
                                 <td styleCode="Toprule">(0%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Body as a Whole - General Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Pain</td>
                                 <td styleCode="Toprule">105</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">88</td>
                                 <td styleCode="Toprule">(5%)</td>
                                 <td styleCode="Toprule">103</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">99</td>
                                 <td styleCode="Toprule">(6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Fatigue</td>
                                 <td styleCode="Toprule">95</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">93</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">97</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">90</td>
                                 <td styleCode="Toprule">(5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Back Pain</td>
                                 <td styleCode="Toprule">76</td>
                                 <td styleCode="Toprule">(5%)</td>
                                 <td styleCode="Toprule">77</td>
                                 <td styleCode="Toprule">(5%)</td>
                                 <td styleCode="Toprule">74</td>
                                 <td styleCode="Toprule">(4%)</td>
                                 <td styleCode="Toprule">65</td>
                                 <td styleCode="Toprule">(4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Accidental Injury</td>
                                 <td styleCode="Toprule">42</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">24</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">51</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">37</td>
                                 <td styleCode="Toprule">(2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Malaise</td>
                                 <td styleCode="Toprule">27</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">23</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">26</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">22</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Asthenia</td>
                                 <td styleCode="Toprule">29</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">19</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">17</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">18</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Syncope</td>
                                 <td styleCode="Toprule">17</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">13</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">8</td>
                                 <td styleCode="Toprule">(0%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Psychiatric Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule" valign="top">        Amnesia</td>
                                 <td styleCode="Toprule">39</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">40</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">57</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">34</td>
                                 <td styleCode="Toprule">(2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Confusion</td>
                                 <td styleCode="Toprule">18</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">9</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">22</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">15</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Anorexia</td>
                                 <td styleCode="Toprule">19</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">17</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">10</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">15</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Somnolence</td>
                                 <td styleCode="Toprule">20</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">13</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">18</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">9</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Musculoskeletal System Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Arthralgia</td>
                                 <td styleCode="Toprule">91</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">75</td>
                                 <td styleCode="Toprule">(5%)</td>
                                 <td styleCode="Toprule">91</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">76</td>
                                 <td styleCode="Toprule">(5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Arthritis</td>
                                 <td styleCode="Toprule">34</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">25</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">17</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">19</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Arthrosis</td>
                                 <td styleCode="Toprule">18</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">22</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">13</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">14</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Myalgia</td>
                                 <td styleCode="Toprule">20</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">11</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">11</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Respiratory System Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Coughing</td>
                                 <td styleCode="Toprule">25</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">18</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">32</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">21</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Upper Respiratory Tract<br/>        Infection</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">9</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">14</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Cardiovascular Disorders, General</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule" valign="top">        Cardiac Failure</td>
                                 <td styleCode="Toprule">26</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">17</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">30</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">25</td>
                                 <td styleCode="Toprule">(2%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Platelet, Bleeding and Clotting Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule" valign="top">        Hemorrhage NOS</td>
                                 <td styleCode="Toprule">52</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">24</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">46</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">24</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Epistaxis</td>
                                 <td styleCode="Toprule">39</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">45</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">25</td>
                                 <td styleCode="Toprule">(2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Purpura</td>
                                 <td styleCode="Toprule">23</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">8</td>
                                 <td styleCode="Toprule">(0%)</td>
                                 <td styleCode="Toprule">9</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">7</td>
                                 <td styleCode="Toprule">(0%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Neoplasm</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Neoplasm NOS</td>
                                 <td styleCode="Toprule">28</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">23</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">20</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="9">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Red Blood Cell Disorders</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Anemia</td>
                                 <td styleCode="Toprule">27</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">19</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">9</td>
                                 <td styleCode="Toprule">(1%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <br/>
                        <paragraph ID="p6169122">Discontinuation
due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release
dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table
2)</paragraph>
                        <table ID="t2" cellpadding="1" cellspacing="1" width="1272">
                           <caption>Table 2 Incidence of Adverse Events that Led to the Discontinuation
of Treatment: Adverse Events with an Incidence of ≥1% in the AGGRENOX
Group</caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="6%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="6%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="6%"/>
                              <col align="left" width="4%"/>
                              <col align="left" width="8%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th align="right"> </th>
                                 <th align="center" colspan="7">Treatment Groups</th>
                                 <th align="center"> </th>
                              </tr>
                              <tr>
                                 <th align="right"> </th>
                                 <th align="center" colspan="2" styleCode="Toprule">AGGRENOX</th>
                                 <th align="center" colspan="2" styleCode="Toprule">ER-DP</th>
                                 <th align="center" colspan="2" styleCode="Toprule">ASA</th>
                                 <th align="center" colspan="2" styleCode="Toprule">Placebo</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="9">Note:     ER-DP = extended-release dipyridamole
200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment
groups is BID.  </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Total Number of Patients</content>
                                    </content>
                                 </td>
                                 <td align="center" colspan="2">1650</td>
                                 <td align="center" colspan="2">1654</td>
                                 <td align="center" colspan="2">1649</td>
                                 <td align="center" colspan="2">1649</td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Botrule"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Patients with at least one Adverse
Event<br/>that led to treatment discontinuation</content>
                                    </content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule">
                                    <br/>417</td>
                                 <td styleCode="Toprule">
                                    <br/>(25%)</td>
                                 <td styleCode="Toprule">
                                    <br/>419</td>
                                 <td styleCode="Toprule">
                                    <br/>(25%)</td>
                                 <td styleCode="Toprule">
                                    <br/>318</td>
                                 <td styleCode="Toprule">
                                    <br/>(19%)</td>
                                 <td align="right" styleCode="Toprule">
                                    <br/>352</td>
                                 <td align="center" styleCode="Toprule">
                                    <br/>(21%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Headache</td>
                                 <td styleCode="Toprule">165</td>
                                 <td styleCode="Toprule">(10%)</td>
                                 <td styleCode="Toprule">166</td>
                                 <td styleCode="Toprule">(10%)</td>
                                 <td styleCode="Toprule">57</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td align="right" styleCode="Toprule">69</td>
                                 <td align="center" styleCode="Toprule">(4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Dizziness</td>
                                 <td styleCode="Toprule">85</td>
                                 <td styleCode="Toprule">(5%)</td>
                                 <td styleCode="Toprule">97</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">69</td>
                                 <td styleCode="Toprule">(4%)</td>
                                 <td align="right" styleCode="Toprule">68</td>
                                 <td align="center" styleCode="Toprule">(4%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule">        Nausea</td>
                                 <td styleCode="Toprule">91</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">95</td>
                                 <td styleCode="Toprule">(6%)</td>
                                 <td styleCode="Toprule">51</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td align="right" styleCode="Toprule">53</td>
                                 <td align="center" styleCode="Toprule">(3%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule">        Abdominal Pain</td>
                                 <td styleCode="Toprule">74</td>
                                 <td styleCode="Toprule">(4%)</td>
                                 <td styleCode="Toprule">64</td>
                                 <td styleCode="Toprule">(4%)</td>
                                 <td styleCode="Toprule">56</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td align="right" styleCode="Toprule">52</td>
                                 <td align="center" styleCode="Toprule">(3%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Toprule">        Dyspepsia</td>
                                 <td styleCode="Toprule">59</td>
                                 <td styleCode="Toprule">(4%)</td>
                                 <td styleCode="Toprule">61</td>
                                 <td styleCode="Toprule">(4%)</td>
                                 <td styleCode="Toprule">49</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td align="right" styleCode="Toprule">46</td>
                                 <td align="center" styleCode="Toprule">(3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Vomiting</td>
                                 <td styleCode="Toprule">53</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">52</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">28</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td align="right" styleCode="Toprule">24</td>
                                 <td align="center" styleCode="Toprule">(1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Diarrhea</td>
                                 <td styleCode="Toprule">35</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">41</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">9</td>
                                 <td styleCode="Toprule">(&lt;1%)</td>
                                 <td align="right" styleCode="Toprule">16</td>
                                 <td align="center" styleCode="Toprule"> (&lt;1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Stroke</td>
                                 <td styleCode="Toprule">39</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">48</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td styleCode="Toprule">57</td>
                                 <td styleCode="Toprule">(3%)</td>
                                 <td align="right" styleCode="Toprule">73</td>
                                 <td align="center" styleCode="Toprule">(4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Transient Ischemic Attack</td>
                                 <td styleCode="Toprule">35</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">40</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td styleCode="Toprule">26</td>
                                 <td styleCode="Toprule">(2%)</td>
                                 <td align="right" styleCode="Toprule">48</td>
                                 <td align="center" styleCode="Toprule">(3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Angina Pectoris</td>
                                 <td styleCode="Toprule">23</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">20</td>
                                 <td styleCode="Toprule">(1%)</td>
                                 <td styleCode="Toprule">16</td>
                                 <td styleCode="Toprule">(&lt;1%)</td>
                                 <td align="right" styleCode="Toprule">26</td>
                                 <td align="center" styleCode="Toprule">(2%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p7468122">Headache was most notable in the
first month of treatment.</paragraph>
                        <paragraph ID="p7471122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Other Adverse Events</content>
                           </content>
                           <br/> Adverse
reactions that occurred in less than 1% of patients treated with AGGRENOX
in the ESPS2 study and that were medically judged to be possibly related
to either dipyridamole or aspirin are listed below.</paragraph>
                        <paragraph ID="p7686122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Body as a Whole:</content>
                           </content> Allergic reaction, fever</paragraph>
                        <paragraph ID="p7694122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Cardiovascular: </content>
                           </content>Hypotension</paragraph>
                        <paragraph ID="p7702122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Central Nervous System: </content>
                           </content>Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial
hemorrhage, subarachnoid hemorrhage</paragraph>
                        <paragraph ID="p7710122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Gastrointestinal: </content>
                           </content>Gastritis,
ulceration and perforation</paragraph>
                        <paragraph ID="p7718122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Hearing and Vestibular Disorders: </content>
                           </content>Tinnitus,
and deafness. Patients with high frequency hearing loss may have difficulty
perceiving tinnitus. In these patients, tinnitus cannot be used as
a clinical indicator of salicylism</paragraph>
                        <paragraph ID="p7726122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Heart Rate and Rhythm Disorders: </content>
                           </content>Tachycardia, palpitation, arrhythmia, supraventricular tachycardia</paragraph>
                        <paragraph ID="p7940122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Liver and Biliary System
Disorders: </content>
                           </content>Cholelithiasis, jaundice, hepatic function
abnormal</paragraph>
                        <paragraph ID="p7948122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Metabolic
and Nutritional Disorders: </content>
                           </content>Hyperglycemia, thirst</paragraph>
                        <paragraph ID="p7956122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Platelet, Bleeding and
Clotting Disorders: </content>
                           </content>Hematoma, gingival bleeding </paragraph>
                        <paragraph ID="p7964122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Psychiatric Disorders: </content>
                           </content>Agitation</paragraph>
                        <paragraph ID="p7972122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Reproductive: </content>
                           </content>Uterine hemorrhage</paragraph>
                        <paragraph ID="p7980122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Respiratory: </content>
                           </content>Hyperpnea,
asthma, bronchospasm, hemoptysis, pulmonary edema</paragraph>
                        <paragraph ID="p8194122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Special Senses Other Disorders: </content>
                           </content>Taste loss </paragraph>
                        <paragraph ID="p8202122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Skin and Appendages Disorders: </content>
                           </content>Pruritus,
urticaria </paragraph>
                        <paragraph ID="p8210122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Urogenital: </content>
                           </content>Renal insufficiency and failure, hematuria</paragraph>
                        <paragraph ID="p8218122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Vascular (Extracardiac) Disorders: </content>
                           </content>Flushing</paragraph>
                        <paragraph ID="p8226122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Laboratory Changes</content>
                           </content>
                           <br/> Over the course
of the 24-month study (ESPS2), patients treated with AGGRENOX showed
a decline (mean change from baseline) in hemoglobin of 0.25 g/dL,
hematocrit of 0.75%, and erythrocyte count of 0.13x10<sup>6</sup>/mm<sup>3</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="21ab6caa-f673-4e48-a81b-13fdbe3b490a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2  Post-Marketing Experience</title>
                     <text>
                        <paragraph ID="p8454122">The following is a list of additional adverse
reactions that have been reported either in the literature or are
from post-marketing spontaneous reports for either dipyridamole or
aspirin. Because these reactions are reported voluntarily from a population
of uncertain size, it is not always possible to estimate reliably
their frequency or establish a causal relationship to drug exposure.
Decisions to include these reactions in labeling are typically based
on one or more of the following factors: (1) seriousness of the reaction,
(2) frequency of reporting, or (3) strength of causal connection to
AGGRENOX.</paragraph>
                        <paragraph ID="p8457122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Body
as a Whole: </content>
                           </content>Hypothermia, chest pain</paragraph>
                        <paragraph ID="p8465122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Cardiovascular: </content>
                           </content>Angina pectoris</paragraph>
                        <paragraph ID="p8473122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Central Nervous System: </content>
                           </content>Cerebral edema</paragraph>
                        <paragraph ID="p8481122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Fluid and Electrolyte: </content>
                           </content>Hyperkalemia, metabolic acidosis, respiratory alkalosis,
hypokalemia</paragraph>
                        <paragraph ID="p8489122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Gastrointestinal: </content>
                           </content>Pancreatitis, Reye syndrome,
hematemesis</paragraph>
                        <paragraph ID="p8497122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Hearing and Vestibular Disorders: </content>
                           </content>Hearing loss</paragraph>
                        <paragraph ID="p8711122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Immune System Disorders: </content>
                           </content>Hypersensitivity, acute anaphylaxis, laryngeal edema</paragraph>
                        <paragraph ID="p8719122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Liver and Biliary System
Disorders: </content>
                           </content>Hepatitis, hepatic failure</paragraph>
                        <paragraph ID="p8727122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Musculoskeletal: </content>
                           </content>Rhabdomyolysis</paragraph>
                        <paragraph ID="p8735122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Metabolic and Nutritional Disorders: </content>
                           </content>Hypoglycemia, dehydration</paragraph>
                        <paragraph ID="p8743122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Platelet, Bleeding and Clotting Disorders: </content>
                           </content>Prolongation of the prothrombin time, disseminated intravascular
coagulation, coagulopathy, thrombocytopenia</paragraph>
                        <paragraph ID="p8751122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Reproductive: </content>
                           </content>Prolonged pregnancy and labor, stillbirths, lower birth weight infants,
antepartum and postpartum bleeding</paragraph>
                        <paragraph ID="p8965122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Respiratory: </content>
                           </content>Tachypnea, dyspnea</paragraph>
                        <paragraph ID="p8973122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Skin and Appendages Disorders: </content>
                           </content>Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin
hemorrhages such as bruising, ecchymosis, and hematoma</paragraph>
                        <paragraph ID="p8981122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Urogenital: </content>
                           </content>Interstitial nephritis, papillary necrosis, proteinuria</paragraph>
                        <paragraph ID="p8989122">
                           <content styleCode="italics">Vascular (Extracardiac) Disorders:</content> Allergic vasculitis</paragraph>
                        <paragraph ID="p8997122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Other Adverse Events: </content>
                           </content>anorexia, aplastic
anemia, migraine, pancytopenia, thrombocytosis.</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="69fa46f8-ee49-4fa9-a6ca-4f7a0239067a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS</title>
               <effectiveTime value="20151117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l9220122" listType="unordered" styleCode="Disc">
                           <item>Co-administration with anticoagulants, antiplatelets, or
NSAIDs can increase risk of bleeding <linkHtml href="#Section_7.1">(7.1)</linkHtml>
                           </item>
                           <item>Decreased renal function can occur with co-administration
with NSAIDs <linkHtml href="#Section_7.1">(7.1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="2096e837-bfec-45c0-b11b-cc361d789c29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1  Drug Interaction
Study Information Obtained From Literature</title>
                     <text>
                        <paragraph ID="p9253122">
                           <content styleCode="italics">Adenosine</content>
                           <br/>Dipyridamole has
been reported to increase the plasma levels and cardiovascular effects
of adenosine. Adjustment of adenosine dosage may be necessary.</paragraph>
                        <paragraph ID="p253581222">
                           <content styleCode="italics">Angiotensin Converting Enzyme
(ACE) Inhibitors</content>
                           <br/>Due to the indirect effect of
aspirin on the renin-angiotensin conversion pathway, the hyponatremic
and hypotensive effects of ACE inhibitors may be diminished by concomitant
administration of aspirin.</paragraph>
                        <paragraph ID="p253531022">
                           <content styleCode="italics">Acetazolamide</content>
                           <br/>Concurrent use of aspirin and acetazolamide
can lead to high serum concentrations of acetazolamide (and toxicity)
due to competition at the renal tubule for secretion.</paragraph>
                        <paragraph ID="p28678422">
                           <content styleCode="italics">Anticoagulants and Antiplatelets</content>
                           <br/>Patients taking AGGRENOX in combination with anticoagulants, antiplatelets,
or any substance impacting coagulation are at increased risk for bleeding.
 Aspirin can displace warfarin from protein binding sites, leading
to prolongation of both the prothrombin time and the bleeding time.
Aspirin can increase the anticoagulant activity of heparin, increasing
bleeding risk.</paragraph>
                        <paragraph ID="p120633301447303051">
                           <content styleCode="italics">Anagrelide</content>
                           <br/>Patients taking aspirin in combination
with anagrelide are at an increased risk of bleeding.</paragraph>
                        <paragraph ID="p28690522">
                           <content styleCode="italics">Anticonvulsants</content>
                           <br/>Salicylic
acid can displace protein-bound phenytoin and valproic acid, leading
to a decrease in the total concentration of phenytoin and an increase
in serum valproic acid levels.</paragraph>
                        <paragraph ID="p28701522">
                           <content styleCode="italics">Beta Blockers</content>
                           <br/>The hypotensive effects
of beta blockers may be diminished by the concomitant administration
of aspirin due to inhibition of renal prostaglandins, leading to decreased
renal blood flow and salt and fluid retention.</paragraph>
                        <paragraph ID="p28707622">
                           <content styleCode="italics">Cholinesterase Inhibitors</content>
                           <br/>Dipyridamole may counteract the anticholinesterase effect of cholinesterase
inhibitors, thereby potentially aggravating myasthenia gravis.</paragraph>
                        <paragraph ID="p28719522">
                           <content styleCode="italics">Diuretics</content>
                           <br/>The
effectiveness of diuretics in patients with underlying renal or cardiovascular
disease may be diminished by the concomitant administration of aspirin
due to inhibition of renal prostaglandins, leading to decreased renal
blood flow and salt and fluid retention.</paragraph>
                        <paragraph ID="p28934422">
                           <content styleCode="italics">Methotrexate</content>
                           <br/>Salicylate
can inhibit renal clearance of methotrexate, leading to bone marrow
toxicity, especially in the elderly or renal impaired.</paragraph>
                        <paragraph ID="p28943422">
                           <content styleCode="italics">Nonsteroidal Anti-Inflammatory
Drugs (NSAIDs)</content>
                           <br/>The concurrent use of aspirin with
other NSAIDs may increase bleeding or lead to decreased renal function.</paragraph>
                        <paragraph ID="p28952422">
                           <content styleCode="italics">Oral Hypoglycemics</content>
                           <br/>Moderate doses of aspirin may increase the effectiveness of oral
hypoglycemic drugs, leading to hypoglycemia.</paragraph>
                        <paragraph ID="p28961422">
                           <content styleCode="italics">Uricosuric Agents (probenecid and sulfinpyrazone)</content>
                           <br/>Salicylates antagonize the uricosuric action of uricosuric
agents.</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="125fe7bc-56ac-4757-8800-a708befffcb2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20151117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="l28956222" listType="unordered" styleCode="Disc">
                           <item>Pregnancy Category D <linkHtml href="#Section_8.1">(8.1)</linkHtml>
                           </item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="7e85d651-11e1-40a3-b79d-2540ee2a7206"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <text>
                        <paragraph ID="p9775122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Teratogenic Effects, Pregnancy Category D.</content>
                           </content> [<content styleCode="italics">
                              <content styleCode="emphasis">see Warnings and Precautions <linkHtml href="#Section_5.4">(5.4)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="f9324ae3-6894-4421-9d70-6904ba0bcf2d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2  Labor and Delivery</title>
                     <text>
                        <paragraph ID="p10003122">Aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. Because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pregnancy [<content styleCode="italics">
                              <content styleCode="emphasis">see Warnings and Precautions <linkHtml href="#Section_5.4">(5.4)</linkHtml>
                              </content>
                           </content>], avoid AGGRENOX in the third trimester of pregnancy and during labor and delivery.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="a67ee731-889b-4f76-8c74-659f2c17a6b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3  Nursing Mothers</title>
                     <text>
                        <paragraph ID="p10020122">Both dipyridamole and aspirin are excreted in human milk. Exercise caution when AGGRENOX capsules are administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="606592cc-2946-4de3-af22-fb9c96ffa404"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4  Pediatric Use</title>
                     <text>
                        <paragraph ID="p10028122">Safety and effectiveness of AGGRENOX in pediatric patients have not been studied. Due to the aspirin component, use of this product in the pediatric population is not recommended [<content styleCode="italics">
                              <content styleCode="emphasis">see Contraindications <linkHtml href="#Section_4.3">(4.3)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="9d6b3892-e061-4bc6-bbf8-b88b556a4d7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5  Geriatric Use </title>
                     <text>
                        <paragraph ID="p10251122">Of the total number of subjects in ESPS2, 61 percent were 65 and over, while 27 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [<content styleCode="italics">
                              <content styleCode="emphasis">see Clinical Pharmacology <linkHtml href="#Section_12.3">(12.3)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="8c6631a0-b703-40ba-b7e0-76e1d083e4c2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6  Patients with Severe
Hepatic or Severe Renal Dysfunction</title>
                     <text>
                        <paragraph ID="p10268122">AGGRENOX has not been studied in patients with hepatic
or renal impairment. Avoid using aspirin containing products, such
as AGGRENOX in patients with severe hepatic or severe renal (glomerular
filtration rate &lt;10 mL/min) dysfunction [<content styleCode="italics">
                              <content styleCode="emphasis">see
Warnings and Precautions <linkHtml href="#Section_5.2">(5.2</linkHtml>, <linkHtml href="#Section_5.3">5.3)</linkHtml> and Clinical Pharmacology <linkHtml href="#Section_12.3">(12.3)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="c9fb25dd-c263-432c-b728-60bf24b59813"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph ID="p10499122">Because
of the dose ratio of dipyridamole to aspirin, overdosage of AGGRENOX
is likely to be dominated by signs and symptoms of dipyridamole overdose.
In case of real or suspected overdose, seek medical attention or contact
a Poison Control Center immediately. Careful medical management is
essential.</paragraph>
                  <paragraph ID="p10502122">Based upon the known
hemodynamic effects of dipyridamole, symptoms such as warm feeling,
flushes, sweating, restlessness, feeling of weakness and dizziness
may occur. A drop in blood pressure and tachycardia might also be
observed.</paragraph>
                  <paragraph ID="p10505122">Salicylate toxicity
may result from acute ingestion (overdose) or chronic intoxication.
Severity of aspirin intoxication is determined by measuring the blood
salicylate level. The early signs of salicylic overdose (salicylism),
including tinnitus (ringing in the ears), occur at plasma concentrations
approaching 200 µg/mL. In severe cases, hyperthermia and hypovolemia
are the major immediate threats to life. Plasma concentrations of
aspirin above 300 µg/mL are clearly toxic. Severe toxic effects are
associated with levels above 400 µg/mL. A single lethal dose of aspirin
in adults is not known with certainty but death may be expected at
30 g.</paragraph>
                  <paragraph ID="p10509122">Treatment of overdose consists
primarily of supporting vital functions, increasing drug elimination,
and correcting acid-base disturbances. Consider gastric emptying and/or
lavage as soon as possible after ingestion, even if the patient has
vomited spontaneously. After lavage and/or emesis, administration
of activated charcoal as a slurry may be beneficial if less than 3
hours have passed since ingestion. Charcoal absorption should not
be employed prior to emesis and lavage. Follow acid-base status closely
with serial blood gas and serum pH measurements. Maintain fluid and
electrolyte balance. Administer replacement fluid intravenously and
augment with correction of acidosis. Treatment may require the use
of a vasopressor. Infusion of glucose may be required to control hypoglycemia.</paragraph>
                  <paragraph ID="p10512122">Administration of xanthine derivatives
(e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole
overdose.  Plasma electrolytes and pH should be monitored serially
to promote alkaline diuresis of salicylate if renal function is normal.
 In patients with renal insufficiency or in cases of life-threatening
intoxication, dialysis is usually required to treat salicylic overdose;
however, since dipyridamole is highly protein bound, dialysis is not
likely to remove dipyridamole. Exchange transfusion may be indicated
in infants and young children.</paragraph>
               </text>
               <effectiveTime value="20151117"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="8ba1bd0c-1307-493d-9725-7a8af93f7833"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph ID="p10520122">AGGRENOX is a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release form and 25 mg aspirin, as an immediate-release sugar-coated tablet. In addition, each capsule contains the following inactive ingredients: acacia, aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone, hypromellose, hypromellose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide and triacetin.</paragraph>
                  <paragraph ID="p10523122">Each capsule shell contains gelatin, red iron oxide and yellow iron oxide, titanium dioxide and water.</paragraph>
               </text>
               <effectiveTime value="20131205"/>
               <component>
                  <section ID="Section_11.1">
                     <id root="253d4d1d-6460-4ebe-b5d4-43b16e51f57b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph ID="p10530122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Dipyridamole</content>
                           </content>
                           <br/>Dipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8-Dipiperidinopyrimido[5,4-<content styleCode="italics">
                              <content styleCode="emphasis">d</content>
                           </content>]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:</paragraph>
                        <renderMultiMedia referencedObject="g13591322"/>
                        <paragraph ID="p10755122">Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and is practically insoluble in water.</paragraph>
                     </text>
                     <effectiveTime value="20131205"/>
                     <component>
                        <observationMedia ID="g13591322">
                           <text>aggrenox-struct1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="aggrenox-struct1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_11.2">
                     <id root="f5fce503-59a3-4950-999a-1a804dc90246"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph ID="p10762122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Aspirin</content>
                           </content>
                           <br/>The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy)-, and has the following structural formula:</paragraph>
                        <renderMultiMedia referencedObject="g13611322"/>
                        <paragraph ID="p10775122">Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid soluble and slightly soluble in water.</paragraph>
                     </text>
                     <effectiveTime value="20131205"/>
                     <component>
                        <observationMedia ID="g13611322">
                           <text>aggrenox-struct2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="aggrenox-struct2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="f8c668c4-6638-4475-a69b-fa36ac2859d7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20151117"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="e2bb43f8-26e1-49e3-a699-e15255738e26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1  Mechanism of Action</title>
                     <text>
                        <paragraph ID="p10788122">The antithrombotic action of AGGRENOX is the result of the additive antiplatelet effects of dipyridamole and aspirin.</paragraph>
                     </text>
                     <effectiveTime value="20120918"/>
                     <component>
                        <section ID="Section_12.1.1">
                           <id root="c411df85-2fc6-40c4-9eff-e860275a1ebb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph ID="p10795122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Dipyridamole</content>
                                 </content>
                                 <br/>Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes <content styleCode="italics">
                                    <content styleCode="emphasis">in vitro</content>
                                 </content> and <content styleCode="italics">
                                    <content styleCode="emphasis">in vivo</content>
                                 </content>; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5–1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A<sub>2</sub>-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). </paragraph>
                              <paragraph ID="p11026122">Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).</paragraph>
                           </text>
                           <effectiveTime value="20120918"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_12.1.2">
                           <id root="291fc74e-ee69-4380-8748-c09817aa7d27"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph ID="p11033122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Aspirin</content>
                                 </content>
                                 <br/>Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A<sub>2</sub>, a powerful inducer of platelet aggregation and vasoconstriction.</paragraph>
                           </text>
                           <effectiveTime value="20120307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="ee1e2976-b7ff-4b64-8c0f-71d6bb168e09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.2  Pharmacodynamics </title>
                     <text>
                        <paragraph ID="p11051122">The effect of either agent on the other's inhibition of platelet reactivity has not been evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="7f052dc8-c365-4f8d-9023-0a02f21882d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph ID="p11265122">There are no significant interactions between aspirin and dipyridamole. The kinetics of the components are unchanged by their co-administration as AGGRENOX.</paragraph>
                     </text>
                     <effectiveTime value="20151117"/>
                     <component>
                        <section ID="Section_12.3.1">
                           <id root="629b9912-e780-4c20-8440-195987be30ff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph ID="p11272122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Dipyridamole</content>
                                 </content>
                                 <br/>
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Absorption</content>
                                 </content>
                                 <br/>Peak plasma levels of dipyridamole are achieved 2 hours (range 1–6 hours) after administration of a daily dose of 400 mg AGGRENOX (given as 200 mg BID). The peak plasma concentration at steady-state is 1.98 µg/mL (1.01–3.99 µg/mL) and the steady-state trough concentration is 0.53 µg/mL (0.18–1.01 µg/mL).</paragraph>
                              <paragraph ID="p11287122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Effect of Food</content>
                                 </content>
                                 <br/>When AGGRENOX capsules were taken with a high fat meal, dipyridamole peak plasma levels (C<sub>max</sub>) and total absorption (AUC) were decreased at steady-state by 20-30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma concentrations, this food effect is not considered clinically relevant.</paragraph>
                              <paragraph ID="p11300122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Distribution</content>
                                 </content>
                                 <br/>Dipyridamole is highly lipophilic (log P=3.71, pH=7); however, it has been shown that the drug does not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma proteins, predominantly to alpha 1-acid glycoprotein and albumin.</paragraph>
                              <paragraph ID="p11309122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Metabolism and Elimination</content>
                                 </content>
                                 <br/> Dipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area under the curve, AUC) and a prolonged elimination phase λ<sub>z</sub> with a half-life of about 15.5 hours. Due to the extended absorption phase of the dipyridamole component, only the terminal phase is apparent from oral treatment with AGGRENOX which, in Trial 9.123 was 13.6 hours.</paragraph>
                              <paragraph ID="p11529122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Special Populations</content>
                                 </content>
                              </paragraph>
                              <paragraph ID="p11537122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Geriatric Patients</content>
                                 </content>: In ESPS2 [<content styleCode="italics">
                                    <content styleCode="emphasis">see Clinical Studies <linkHtml href="#Section_14">(14)</linkHtml>
                                    </content>
                                 </content>], plasma concentrations (determined as AUC) of dipyridamole in healthy elderly subjects (&gt;65 years) were about 40% higher than in subjects younger than 55 years receiving treatment with AGGRENOX. </paragraph>
                              <paragraph ID="p11554122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Hepatic Dysfunction</content>
                                 </content>: No study has been conducted with AGGRENOX in patients with hepatic dysfunction.</paragraph>
                              <paragraph ID="p11562122">In a study conducted with an intravenous formulation of dipyridamole, patients with mild to severe hepatic insufficiency showed no change in plasma concentrations of dipyridamole but showed an increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed without restriction as long as there is no evidence of hepatic failure.</paragraph>
                              <paragraph ID="p11565122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Renal Dysfunction</content>
                                 </content>: No study has been conducted with AGGRENOX in patients with renal dysfunction.</paragraph>
                              <paragraph ID="p11779122">In ESPS2 patients [<content styleCode="italics">
                                    <content styleCode="emphasis">see Clinical Studies <linkHtml href="#Section_14">(14)</linkHtml>
                                    </content>
                                 </content>], with creatinine clearances ranging from about 15 mL/min to &gt;100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite if data were corrected for differences in age.</paragraph>
                           </text>
                           <effectiveTime value="20120307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_12.3.2">
                           <id root="d435788a-ebac-4c07-b167-6dc6666c5900"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph ID="p11795122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Aspirin</content>
                                 </content>
                                 <br/>
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Absorption</content>
                                 </content>
                                 <br/>Peak plasma levels of aspirin are achieved 0.63 hours
(0.5–1 hour) after administration of a 50 mg aspirin daily dose from
AGGRENOX (given as 25 mg BID). The peak plasma concentration at steady-state
is 319 ng/mL (175–463 ng/mL). Aspirin undergoes moderate hydrolysis
to salicylic acid in the liver and the gastrointestinal wall, with
50%–75% of an administered dose reaching the systemic circulation
as intact aspirin.</paragraph>
                              <paragraph ID="p11810122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Effect of Food</content>
                                 </content>
                                 <br/>When AGGRENOX
capsules were taken with a high fat meal, there was no difference
for aspirin in AUC at steady-state, and the approximately 50% decrease
in C<sub>max</sub> was not considered clinically relevant
based on a similar degree of cyclooxygenase inhibition comparing the
fed and fasted state.</paragraph>
                              <paragraph ID="p11823122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Distribution</content>
                                 </content>
                                 <br/>Aspirin
is poorly bound to plasma proteins and its apparent volume of distribution
is low (10 L). Its metabolite, salicylic acid, is highly bound to
plasma proteins, but its binding is concentration-dependent (nonlinear).
At low concentrations (&lt;100 µg/mL), approximately 90% of salicylic
acid is bound to albumin. Salicylic acid is widely distributed to
all tissues and fluids in the body, including the central nervous
system, breast milk, and fetal tissues. Early signs of salicylate
overdose (salicylism), including tinnitus (ringing in the ears), occur
at plasma concentrations approximating 200 µg/mL [<content styleCode="italics">
                                    <content styleCode="emphasis">see Adverse Reactions <linkHtml href="#Section_6">(6)</linkHtml> and Overdosage <linkHtml href="#Section_10">(10)</linkHtml>
                                    </content>
                                 </content>].</paragraph>
                              <paragraph ID="p12052122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Metabolism and Elimination</content>
                                 </content>
                                 <br/>Aspirin is rapidly hydrolyzed in plasma to
salicylic acid, with a half-life of 20 minutes. Plasma levels of aspirin
are essentially undetectable 2–2.5 hours after dosing and peak salicylic
acid concentrations occur 1 hour (range: 0.5–2 hours) after administration
of aspirin. Salicylic acid is primarily conjugated in the liver to
form salicyluric acid, a phenolic glucuronide, an acyl glucuronide,
and a number of minor metabolites. Salicylate metabolism is saturable
and total body clearance decreases at higher serum concentrations
due to the limited ability of the liver to form both salicyluric acid
and phenolic glucuronide. Following toxic doses (10–20 g), the plasma
half-life may be increased to over 20 hours.</paragraph>
                              <paragraph ID="p12062122">The elimination of acetylsalicylic acid follows first-order
kinetics with AGGRENOX and has a half-life of 0.33 hours. The half-life
of salicylic acid is 1.71 hours. Both values correspond well with
data from the literature at lower doses which state a resultant half-life
of approximately 2–3 hours. At higher doses, the elimination of salicylic
acid follows zero-order kinetics (i.e., the rate of elimination is
constant in relation to plasma concentration), with an apparent half-life
of 6 hours or higher. Renal excretion of unchanged drug depends upon
urinary pH. As urinary pH rises above 6.5, the renal clearance of
free salicylate increases from &lt;5% to &gt;80%. Alkalinization of the
urine is a key concept in the management of salicylate overdose [<content styleCode="italics">
                                    <content styleCode="emphasis">see Overdosage <linkHtml href="#Section_10">(10)</linkHtml>
                                    </content>
                                 </content>]. Following therapeutic doses, about 10% is excreted as
salicylic acid and 75% as salicyluric acid, as the phenolic and acyl
glucuronides, in urine.</paragraph>
                              <paragraph ID="p12075122">
                                 <content styleCode="underline">
                                    <content styleCode="emphasis">Special Populations</content>
                                 </content>
                                 <br/>
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Hepatic Dysfunction</content>
                                 </content>: Avoid aspirin
in patients with severe hepatic insufficiency.</paragraph>
                              <paragraph ID="p12295122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Renal Dysfunction</content>
                                 </content>: Avoid aspirin in patients with severe renal failure (glomerular
filtration rate less than 10 mL/min).</paragraph>
                              <br/>
                              <paragraph ID="p25127422">
                                 <content styleCode="italics">AGGRENOX</content>
                                 <br/>
                                 <content styleCode="underline">Drug
Interaction</content>
                                 <br/>A dedicated drug interaction study
was conducted in 60 healthy volunteers to evaluate the effects of
omeprazole 80 mg administered once daily on the pharmacokinetics (PK)
of dipyridamole and the pharmacodynamics (PD) of acetylsalicylic acid
when co-administered with AGGRENOX twice daily. Dipyridamole exposure
(Cmax and AUC) at steady-state were similar with or without omeprazole
co-administration. The pharmacokinetics of acetylsalicylic acid was
not characterized.  However, the antiplatelet activity as measured
by arachidonic acid induced platelet aggregation was similar between
the treatment arms at steady-state.</paragraph>
                           </text>
                           <effectiveTime value="20151117"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="7ab120af-958d-4b1f-9edb-8bc3c5d1f6b3"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20120307"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="04ac6214-eff7-4f39-a3e7-a6bf56629248"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="p12313122">In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m<sup>2</sup> basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats.</paragraph>
                        <paragraph ID="p12320122">Combinations of dipyridamole and aspirin (1:5 ratio) tested negative in the Ames test, <content styleCode="italics">
                              <content styleCode="emphasis">in vivo</content>
                           </content> chromosome aberration tests (in mice and hamsters), oral micronucleus tests (in mice and hamsters) and oral dominant lethal test (in mice). Aspirin, alone, induced chromosome aberrations in cultured human fibroblasts. Mutagenicity tests of dipyridamole alone with bacterial and mammalian cell systems were negative.</paragraph>
                        <paragraph ID="p12329122">Combinations of dipyridamole and aspirin have not been evaluated for effects on fertility and reproductive performance. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m<sup>2</sup> basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m<sup>2</sup> basis). Aspirin inhibits ovulation in rats.</paragraph>
                     </text>
                     <effectiveTime value="20120307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="b37ed7b3-c370-486f-a530-2a56fe1b88df"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="p12551122">ESPS2 (European Stroke Prevention Study-2) was a double-blind, placebo-controlled,
24-month study in which 6602 patients over the age of 18 years had
an ischemic stroke (76%) or transient ischemic attack (TIA, 24%) within
three months prior to entry. Patients were enrolled in 13 European
countries between February 1989 and May 1995 and were randomized to
one of four treatment groups: AGGRENOX (aspirin/extended-release dipyridamole)
25 mg/200 mg; extended-release dipyridamole (ER-DP) 200 mg alone;
aspirin (ASA) 25 mg alone; or placebo. The mean age in this population
was 66.7 years with 58% of them being males. Patients received one
capsule twice daily (morning and evening). Efficacy assessments included
analyses of stroke (fatal or nonfatal) and death (from all causes)
as confirmed by a blinded morbidity and mortality assessment group.
There were no differences with regard to efficacy based on age or
gender; patients who were older had a trend towards more events.</paragraph>
               </text>
               <effectiveTime value="20151117"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="79fdbf8c-d352-4c19-9350-d3adcd08d65b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph ID="p12558122">
                           <content styleCode="italics">
                              <content styleCode="emphasis">Stroke Endpoint</content>
                           </content>
                           <br/>AGGRENOX reduced the risk of stroke by 22.1%
compared to aspirin 50 mg/day alone (p = 0.008) and reduced the risk
of stroke by 24.4% compared to extended-release dipyridamole 400 mg/day
alone (p = 0.002) (Table 3). AGGRENOX reduced the risk of stroke by
36.8% compared to placebo (p &lt;0.001).</paragraph>
                        <table ID="t4" width="100%">
                           <caption>Table 3  Summary of First Stroke (Fatal or Nonfatal): ESPS2:
Intent-to-Treat Population</caption>
                           <col align="left" width="20%"/>
                           <col align="left"/>
                           <col align="left"/>
                           <col align="left"/>
                           <col align="center"/>
                           <col align="center"/>
                           <col align="center"/>
                           <thead>
                              <tr>
                                 <th> </th>
                                 <th align="left">Total<br/>Number<br/>of Patients<br/>n</th>
                                 <th align="left">Number of Patients<br/>With<br/>Stroke
Within 2 Years<br/>n (%)</th>
                                 <th align="left">Kaplan-Meier Estimate<br/>of Survival at 2
Years<br/>(95% C.I.)</th>
                                 <th align="left">Gehan-Wilcoxon<br/>Test<br/>P-value</th>
                                 <th align="left">Risk Reduction<br/>at 2 Years</th>
                                 <th align="left">Odds Ratio<br/>(95% C.I.)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <sup>a</sup>0.010 &lt;p‑value
≤0.050; <sup>b</sup>p‑value ≤0.010.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">Note:   ER-DP = extended-release dipyridamole
200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment
groups is BID.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="7"> </td>
                              </tr>
                              <tr>
                                 <td colspan="7">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Individual Treatment<br/>Group</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        AGGRENOX</td>
                                 <td styleCode="Toprule">1650</td>
                                 <td styleCode="Toprule">157 ( 9.5%)</td>
                                 <td styleCode="Toprule">89.9% (88.4%, 91.4%)</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        ER-DP</td>
                                 <td styleCode="Toprule">1654</td>
                                 <td styleCode="Toprule">211 (12.8%)</td>
                                 <td styleCode="Toprule">86.7% (85.0%, 88.4%)</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        ASA</td>
                                 <td styleCode="Toprule">1649</td>
                                 <td styleCode="Toprule">206 (12.5%)</td>
                                 <td styleCode="Toprule">87.1% (85.4%, 88.7%)</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        Placebo</td>
                                 <td styleCode="Toprule">1649</td>
                                 <td styleCode="Toprule">250 (15.2%)</td>
                                 <td styleCode="Toprule">84.1% (82.2%, 85.9%)</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode="Toprule"> </td>
                              </tr>
                              <tr>
                                 <td colspan="7">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">Pairwise Treatment Group Comparisons</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        AGGRENOX        vs.<br/>                ER-DP</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td styleCode="Toprule">0.002<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule">24.4%</td>
                                 <td align="left" styleCode="Toprule">0.72 (0.58, 0.90)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        AGGRENOX        vs.<br/>                ASA</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td styleCode="Toprule">0.008<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule">22.1%</td>
                                 <td align="left" styleCode="Toprule">0.74 (0.59, 0.92)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        AGGRENOX        vs.<br/>                Placebo</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td styleCode="Toprule">&lt;0.001<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule">36.8%</td>
                                 <td align="left" styleCode="Toprule">0.59 (0.48, 0.73)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        ER-DP vs. Placebo</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td styleCode="Toprule">0.036<sup>a</sup>
                                 </td>
                                 <td styleCode="Toprule">16.5%</td>
                                 <td align="left" styleCode="Toprule">0.82 (0.67, 1.00)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule">        ASA vs. Placebo</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td align="left" styleCode="Toprule">-</td>
                                 <td styleCode="Toprule">0.009<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule">18.9%</td>
                                 <td align="left" styleCode="Toprule">0.80 (0.66, 0.97)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p14115122">
                           <content styleCode="bold">
                              <content styleCode="emphasis">ESPS2: Cumulative
Stroke Rate (Fatal or Nonfatal)</content>
                           </content>
                           <br/>Over
24 months of Follow-UP</paragraph>
                        <renderMultiMedia referencedObject="mm231"/>
                     </text>
                     <effectiveTime value="20151117"/>
                     <component>
                        <section ID="Section_14.1.1">
                           <id root="647d2b21-5c29-4818-8167-f2aaf3f786d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph ID="p14336122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Combined Stroke or Death Endpoint</content>
                                 </content>
                                 <br/>In ESPS2, AGGRENOX reduced the risk of stroke or death by 12.1% compared to aspirin alone and by 10.3% compared to extended-release dipyridamole alone. These results were not statistically significant. AGGRENOX reduced the risk of stroke or death by 24.2% compared to placebo.</paragraph>
                           </text>
                           <effectiveTime value="20120307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_14.1.2">
                           <id root="f7ecacf5-2a44-4c08-b74e-3ccffaa5775c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph ID="p14349122">
                                 <content styleCode="italics">
                                    <content styleCode="emphasis">Death Endpoint</content>
                                 </content>
                                 <br/> The incidence rate of all-cause mortality was
11.3% for AGGRENOX, 11.0% for aspirin alone, 11.4% for extended-release
dipyridamole alone and 12.3% for placebo alone. The differences between
the AGGRENOX, aspirin alone and extended-release dipyridamole alone
treatment groups were not statistically significant. These incidence
rates for AGGRENOX and aspirin alone are consistent with previous
aspirin studies in stroke and TIA patients.</paragraph>
                           </text>
                           <effectiveTime value="20151117"/>
                        </section>
                     </component>
                     <component>
                        <observationMedia ID="mm231">
                           <text>Figure 1.</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="aggrenox-figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="a1c250ff-53a4-43bb-90b1-80b07042bc78"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="p14363122">AGGRENOX capsules are available as a hard gelatin capsule, with a red cap and an ivory-colored body, containing yellow extended-release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release aspirin. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".</paragraph>
                  <paragraph ID="p14366122">AGGRENOX capsules are supplied in unit-of-use bottles of 60 capsules (NDC 0597-0001-60).</paragraph>
                  <paragraph ID="p14369122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)</content>
                     </content> [see USP Controlled Room Temperature]. Protect from excessive moisture.</paragraph>
               </text>
               <effectiveTime value="20120307"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="a5c93d44-1ef0-430b-a433-1908b628e5ac"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="p14382122">Advise the patient to read the FDA-approved patient
labeling (Patient Information).</paragraph>
                  <br/>
                  <list ID="l243549301447303444" listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Risk of Bleeding</content>
                        <br/>Inform patients
that as with other antiplatelet agents, there is a general risk of
bleeding including intracranial and gastrointestinal bleeding. Inform
patients about the signs and symptoms of bleeding, including occult
bleeding. Tell patients to notify their physician if they are prescribed
any drug which may increase risk of bleeding.<br/>
                        <br/>Counsel patients who consume three or more alcoholic drinks daily
about the bleeding risks involved with chronic, heavy alcohol use
while taking aspirin.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Pregnancy</content>
                        <br/>Inform patients that aspirin
is known to be harmful to fetuses and ask the patient to notify them
if they are or become pregnant.</item>
                     <item>
                        <content styleCode="bold">Headaches</content>
                        <br/>Some patients may experience
headaches upon treatment initiation; these are usually transient.
 In case of intolerable headaches, tell patients to contact their
physician.</item>
                     <item>
                        <content styleCode="bold">Dosage and Administration</content>
                        <br/>Tell patients
that AGGRENOX capsules should be swallowed whole, and not chewed or
crushed.  If you miss a dose, continue with your next dose on your
regular schedule. Do not take a double dose.</item>
                     <item>
                        <content styleCode="bold">Storage</content>
                        <br/>Inform patients to protect
AGGRENOX from moisture.</item>
                  </list>
               </text>
               <effectiveTime value="20151117"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="82342b69-7ce4-48d6-bb2c-28fd6b8caa2c"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph ID="p14848122">Distributed by:<br/> Boehringer
Ingelheim Pharmaceuticals, Inc.<br/> Ridgefield, CT 06877 USA</paragraph>
                  <paragraph ID="p14855122">Licensed from: <br/> Boehringer
Ingelheim International GmbH</paragraph>
                  <paragraph ID="p14860122">Copyright © 2015 Boehringer Ingelheim International GmbH<br/> ALL RIGHTS RESERVED</paragraph>
                  <paragraph ID="p14865122">OT1000MK132015<br/>302420-02</paragraph>
               </text>
               <effectiveTime value="20151117"/>
            </section>
         </component>
         <component>
            <section ID="Section_19">
               <id root="c69035b7-1166-4e97-8621-739339469cf3"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <paragraph ID="p14879122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Patient
Information</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p14886122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Aggrenox<sup>®</sup> (AG-reh-nox)</content>
                     </content>
                     <br/>
                     <content styleCode="bold">
                        <content styleCode="emphasis">(aspirin/extended-release dipyridamole)</content>
                     </content>
                     <br/>
                     <content styleCode="bold">
                        <content styleCode="emphasis">Capsules</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p15111122">Read this Patient Information before you
start taking AGGRENOX and each time you get a refill. There may be
new information. This information does not take the place of talking
to your healthcare provider about your medical condition or your treatment.</paragraph>
                  <paragraph ID="p15114122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">What is AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p15121122">AGGRENOX is a prescription
medicine that contains aspirin and a medicine that is slowly released
in your body, called dipyridamole. AGGRENOX is used to lower the risk
of stroke in people who have had a "mini-stroke" (transient ischemic
attack or TIA) or stroke due to a blood clot.</paragraph>
                  <paragraph ID="p15124122">It is not known if AGGRENOX is safe and effective in
children. See "Who should not take AGGRENOX?"</paragraph>
                  <paragraph ID="p15127122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Who should not take AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p15134122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Do not
take AGGRENOX</content>
                     </content> if you:</paragraph>
                  <list ID="l15142122" listType="unordered" styleCode="Disc">
                     <item>are allergic to any of the ingredients in AGGRENOX. See
the end of this leaflet for a list of ingredients in AGGRENOX.</item>
                     <item>are allergic to non-steroidal anti-inflammatory drugs (NSAIDs)</item>
                     <item>have asthma in combination with runny nose and nasal polyps</item>
                  </list>
                  <paragraph ID="p15153122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Do not give AGGRENOX
to a child or teenager with a viral illness. Reye syndrome, a life-threatening
condition, can happen when aspirin (an ingredient in AGGRENOX) is
used in children and teenagers who have certain viral illnesses.</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p15366122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">What
should I tell my doctor before using AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p15373122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Before taking AGGRENOX,
tell your healthcare provider if you:</content>
                     </content>
                  </paragraph>
                  <list ID="l15380122" listType="unordered" styleCode="Disc">
                     <item>have stomach ulcers</item>
                     <item>have a history of bleeding problems</item>
                     <item>have heart problems</item>
                     <item>have kidney or liver problems</item>
                     <item>have low blood pressure</item>
                     <item>have myasthenia gravis</item>
                     <item>have any other medical conditions</item>
                     <item>are pregnant or plan to become pregnant. AGGRENOX can harm
your unborn baby, especially if you take it in the last (third) trimester
of pregnancy. You should not take AGGRENOX during pregnancy without
first talking to your healthcare provider. Tell your healthcare provider
right away if you become pregnant while taking AGGRENOX.</item>
                     <item>are breast-feeding or plan to breast-feed. AGGRENOX can
pass into your milk and may harm your baby. Talk to your healthcare
provider about the best way to feed your baby if you take AGGRENOX.</item>
                  </list>
                  <paragraph ID="p15409122">
                     <content styleCode="bold">Tell your doctor about all
the medicines you take</content>, including prescription and non-prescription
medicines, vitamins and herbal supplements. AGGRENOX and other medicines
may affect each other causing side effects. AGGRENOX may affect the
way other medicines work, and other medicines may affect how AGGRENOX
works.</paragraph>
                  <paragraph ID="p15623122">Especially tell your healthcare
provider if you take:</paragraph>
                  <list ID="l15626122" listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">a medicine for high blood pressure, irregular
heart beat, or heart failure</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">acetazolamide [Diamox<sup>®</sup>]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">any blood thinner medicines </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">warfarin sodium [Coumadin<sup>®</sup>, Jantoven<sup>®</sup>]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">a heparin medicine</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">anagrelide [Agrylin<sup>®</sup>]</content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">a seizure medicine</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">a medicine for Alzheimer’s disease</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">a water pill</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">methotrexate sodium [Trexall<sup>®</sup>]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">aspirin or a non-steroidal anti-inflammatory
drug (NSAIDs). You should not take NSAIDs during treatment with AGGRENOX.</content>
                        </content> Using these medicines with AGGRENOX can increase your risk
of bleeding.</item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">a medicine for diabetes</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">probenecid [Probalan<sup>®</sup>, Col-Probenecid<sup>®</sup>]</content>
                        </content>
                     </item>
                  </list>
                  <paragraph ID="p15905122">Ask your healthcare provider or pharmacist
if you are not sure if your medicine is one that is listed above. </paragraph>
                  <paragraph ID="p15908122">Know the medicines you take. Keep a list
of them and show your healthcare provider and pharmacist when you
get a new medicine.</paragraph>
                  <paragraph ID="p15911122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">How should I take AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <list ID="l15918122" listType="unordered" styleCode="Disc">
                     <item>Take AGGRENOX exactly as prescribed. Your healthcare provider
will tell you how many AGGRENOX to take and when to take them.</item>
                     <item>Headaches are not uncommon when you first start taking AGGRENOX,
but often lessen as treatment continues. Tell your healthcare provider
if you have a severe headache. Your healthcare provider may change
the instructions for taking AGGRENOX.</item>
                     <item>Swallow AGGRENOX whole. Do not crush or chew the capsules.</item>
                     <item>You can take AGGRENOX with or without food.</item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <content styleCode="emphasis">If you miss a dose, take
your next dose at the usual time. Do not take two doses at one time.</content>
                              </content>
                           </content>
                        </content>
                     </item>
                     <item>If you take more AGGRENOX (overdose) than prescribed, call
your healthcare provider or Poison Control Center, or get emergency
help right away.</item>
                  </list>
                  <paragraph ID="p16152122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Symptoms of an overdose
of AGGRENOX include:</content>
                     </content>
                  </paragraph>
                  <list ID="l16159122" listType="unordered" styleCode="Disc">
                     <item>a warm feeling or flushing</item>
                     <item>sweating</item>
                     <item>restlessness</item>
                     <item>weakness or dizziness</item>
                     <item>a fast heart rate</item>
                     <item>ringing in the ears </item>
                  </list>
                  <paragraph ID="p16385122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">What should I avoid
while using AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <list ID="l16392122" listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">heavy alcohol use.</content>
                        </content> People
who drink three or more alcoholic drinks every day have a higher risk
of bleeding during treatment with AGGRENOX, because it contains aspirin.</item>
                  </list>
                  <paragraph ID="p16402122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">What are the possible
side effects of AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p16409122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">AGGRENOX may cause serious side effects,
including:</content>
                     </content>
                  </paragraph>
                  <list ID="l16416122" listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">increased risk of bleeding.</content>
                        </content> You may bleed more easily during AGGRENOX treatment, and it may
take longer than usual for bleeding to stop. This can include:<list ID="l16424122" listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">bleeding into your brain (intracranial hemorrhage).</content>
                              </content> This can be a medical emergency. Get medical help right away
if you have any of these symptoms while taking AGGRENOX:<list ID="l16432122" listType="unordered" styleCode="Square">
                                 <item>severe headache with drowsiness</item>
                                 <item>confusion or memory change</item>
                                 <item>pass out (become unconscious)<br/>
                                 </item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="emphasis">bleeding in your stomach or intestine.</content>
                              </content>
                              <list ID="l16656122" listType="unordered" styleCode="Square">
                                 <item>stomach pain</item>
                                 <item>heartburn or nausea</item>
                                 <item>vomiting blood or vomit looks like "coffee grounds"</item>
                                 <item>red or bloody stools </item>
                                 <item>black stools that look like tar<br/>
                                 </item>
                              </list>
                           </item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">new or worsening chest pain in some people
with heart disease.</content>
                        </content> Tell your healthcare provider
if you have new chest pain or have any change in your chest pain during
treatment with AGGRENOX.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="emphasis">liver problems,</content>
                        </content> including
increased liver function tests and liver failure. Tell your healthcare
provider if you have any of these symptoms of a liver problem while
taking AGGRENOX:<list ID="l16897122" listType="unordered" styleCode="Disc">
                           <item>loss of appetite</item>
                           <item>pale colored stool</item>
                           <item>stomach area (abdomen) pain</item>
                           <item>yellowing of your skin or whites of your eyes</item>
                           <item>dark urine</item>
                           <item>itching </item>
                        </list>
                     </item>
                  </list>
                  <paragraph ID="p16919122">Call your healthcare provider right
away if you have any of the symptoms listed above.</paragraph>
                  <paragraph ID="p16922122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">The most common side effects of AGGRENOX
include:</content>
                     </content>
                  </paragraph>
                  <list ID="l16929122" listType="unordered" styleCode="Disc">
                     <item>headache</item>
                     <item>upset stomach</item>
                     <item>diarrhea</item>
                  </list>
                  <paragraph ID="p16940122">These are not all the possible side
effects of AGGRENOX. Tell your healthcare provider or pharmacist if
you have any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph ID="p16943122">Call your healthcare provider for medical
advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph ID="p17152122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">How should I store AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <list ID="l17159122" listType="unordered" styleCode="Disc">
                     <item>Store AGGRENOX at 59°F to 86°F (15°C to 30°C).</item>
                     <item>Keep AGGRENOX capsules dry.</item>
                     <item>Safely throw away medicine that is out of date or no longer
needed.</item>
                  </list>
                  <paragraph ID="p17170122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Keep AGGRENOX and
all medicines out of the reach of children.</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p17177122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">General information about
AGGRENOX</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p17184122">Medicines
are sometimes prescribed for purposes other than those listed in the
Patient Information. Do not use AGGRENOX for a condition for which
it was not prescribed. Do not give AGGRENOX to other people, even
if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph ID="p17187122">This Patient Information summarizes the
most important information about AGGRENOX. If you would like more
information, talk with your healthcare provider. You can ask your
pharmacist or healthcare provider for information about AGGRENOX that
is written for health professionals.</paragraph>
                  <paragraph ID="p294401301447304809">For more information, go to <content styleCode="underline">www.Aggrenox.com</content>, scan the code below or call Boehringer Ingelheim Pharmaceuticals,
Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906.</paragraph>
                  <renderMultiMedia referencedObject="g294444301447768299"/>
                  <paragraph ID="p17190122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">What are the ingredients
in AGGRENOX?</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p17197122">
                     <content styleCode="bold">Active Ingredients:</content> dipyridamole in an extended-release
form and aspirin<br/>
                     <content styleCode="bold"> Inactive Ingredients:</content> acacia,
aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone,
hypromellose, hypromellose phthalate, lactose monohydrate, methacrylic
acid copolymer, microcrystalline cellulose, povidone, stearic acid,
sucrose, talc, tartaric acid, titanium dioxide and triacetin. Each
capsule shell contains gelatin, red iron oxide and yellow iron oxide,
titanium dioxide, and water.</paragraph>
               </text>
               <effectiveTime value="20151117"/>
               <component>
                  <observationMedia ID="g294444301447768299">
                     <text>aggrenox-qrcode</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="aggrenox-qrcode.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_20">
               <id root="d3e85860-f194-4f7b-b5d2-8d78c86c5336"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph ID="p17412122">Distributed by:<br/> Boehringer
Ingelheim Pharmaceuticals, Inc.<br/> Ridgefield, CT 06877 USA</paragraph>
                  <paragraph ID="p17419122">Licensed from:<br/> Boehringer Ingelheim
International GmbH</paragraph>
                  <paragraph ID="p17424122">Copyright
© 2015 Boehringer Ingelheim International GmbH<br/> ALL RIGHTS
RESERVED</paragraph>
                  <paragraph ID="p17429122">Revised: November 2015</paragraph>
                  <paragraph ID="p17432122">OT1000MK132015<br/>302420-02</paragraph>
               </text>
               <effectiveTime value="20151117"/>
            </section>
         </component>
         <component>
            <section>
               <id root="07316c0e-61f7-40d0-8f10-d2a235143ed1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Aspirin/ER Dipyridamole</title>
               <text>
                  <renderMultiMedia referencedObject="lbl681513971"/>
               </text>
               <effectiveTime value="20160806"/>
               <component>
                  <observationMedia ID="lbl681513971">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl681513971.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>